Hormone replacement therapy (HRT) has been a topic of interest for women's health, and a recent study suggests it may have a significant impact on dementia risk. The research, published in Alzheimer’s & Dementia, analyzed data from the UK Biobank, focusing on 183,450 postmenopausal women with an average age of 60. The findings indicate that HRT use is associated with a 10% lower risk of all-cause dementia and a 16% lower risk of Alzheimer’s disease over a 13-year follow-up period. This association was particularly strong among women who started the therapy between the ages of 46 and 56, and among those who had undergone surgical menopause. However, starting HRT after age 56 did not show a significant reduction in dementia risk.
Dr. Alexa Fiffick, a board-certified family medicine physician, emphasizes that this is an observational study and cannot establish cause and effect. She notes that while there may be some benefit for certain patients, such as those who go through menopause a little bit younger or have a specific APOE ε4 genotype, more research is needed. The study's limitations include the lack of detailed information on the types of hormone therapy, the way they were administered, and the specific dosages taken. Additionally, the majority of participants were of European ancestry and financially better off, which may limit the generalizability of the findings.
HRT does carry known risks and side effects, such as an increased risk of blood clots with oral estrogen versions, but not with transdermal options. Other types of HRT may impact breast activity, overall inflammation, cardiovascular markers, and cardiometabolic markers. Dr. Fiffick advises that while the study provides valuable insights, it is not a reason to seek out HRT specifically for dementia prevention. Instead, she recommends that women who are experiencing symptoms should consult their doctors and have open conversations about their health.
The researchers plan to conduct randomized controlled trials to further confirm the relationship between HRT and dementia risk. These trials will include various factors such as estrogen-only versus combined therapy, dosage amounts, administration route, treatment duration, age at the start of therapy, menopause type, and potentially APOE genotype. As the field of women's health continues to evolve, these studies will provide valuable data to help women make informed decisions about their bodies and overall well-being.
